CG Oncology (CGON) Non Operating Income (2023 - 2026)
CG Oncology posted quarterly Non Operating Income of -$101000.0 for Q1 2026, down 101.3% year-on-year from $7.8 million in Q1 2025, and down 101.37% on a QoQ basis from $7.4 million in Q4 2025.
CG Oncology (CGON) has 4 years of Non Operating Income data on file, last reported at -$101000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 101.3% year-over-year to -$101000.0; the trailing twelve-month figure through Mar 2026 stood at $21.9 million (down 48.14% YoY), and the FY2025 full-year result was $29.8 million, up 11.84% from the prior year.
- Non Operating Income for Q1 2026 stood at -$101000.0, down from $7.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $26.6 million in Q4 2024 and bottomed at -$101000.0 in Q1 2026.
- The 4-year median for Non Operating Income is $5.5 million (2024), against an average of $5.9 million.
- The widest annual swing landed in 2025, when Non Operating Income jumped 91337.5%; it then plunged 101.3% in 2026.
- A 4-year view of Non Operating Income shows it stood at $2.8 million in 2023, then jumped by 851.07% to $26.6 million in 2024, then plunged by 72.25% to $7.4 million in 2025, then sank by 101.37% to -$101000.0 in 2026.
- The last three Non Operating Income figures came in at -$101000.0 (Q1 2026), $7.4 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101,000.00 |
| Dec 31, 2025 | 7.39 Mn |
| Sep 30, 2025 | 7.32 Mn |
| Jun 30, 2025 | 7.32 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 26.63 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 5.54 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 2.28 Mn |
| Jun 30, 2023 | 713,000.00 |
| Mar 31, 2023 | 1.05 Mn |